Aeterna Zentaris Announces Effective Date of Share Consolidation
01 mai 2024 07h55 HE
|
Aeterna Zentaris Inc
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the previously...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27 mars 2024 08h05 HE
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
15 févr. 2024 17h50 HE
|
Aeterna Zentaris Inc
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials available...
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
09 août 2023 08h05 HE
|
Aeterna Zentaris Inc
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency ...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
23 mars 2023 08h05 HE
|
Aeterna Zentaris Inc
– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing...
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
15 juil. 2022 16h15 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
21 juin 2022 16h01 HE
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
18 mai 2022 08h00 HE
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
21 mars 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
05 janv. 2022 08h36 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...